| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| MCCORMICK FRANK | Director | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO | /s/ Will Solis, Attorney-in-Fact | 08 Sep 2025 | 0001257809 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBIO | Common Stock | Options Exercise | $882,080 | +74,000 | +89% | $11.92 | 157,275 | 05 Sep 2025 | Direct | |
| transaction | BBIO | Common Stock | Sale | $3,933,544 | -74,000 | -47% | $53.16 | 83,275 | 05 Sep 2025 | Direct | F1 |
| holding | BBIO | Common Stock | 879,979 | 05 Sep 2025 | By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBIO | Stock Option (Right to Buy) | Options Exercise | $0 | -74,000 | -47% | $0.000000 | 84,814 | 05 Sep 2025 | Common Stock | 74,000 | $11.92 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F2 | The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. |
Exhibit 24 - Power of Attorney